Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Driving sustainable margin outcomes

Eagers Automotive
3:27pm
February 22, 2024
APE delivered FY23 (vs pcp): revenue +15% to A$9.9bn; underlying NPBT +7% to A$433m; DPS +4% to 74cps. The result was in-line with expectations. Cost management was again a highlight, with APE able to absorb a significant step up in funding costs. ROS at 4.4% (-35bps due to acquisitions/mix) is sector leading. Revenue growth guidance of ~A$1bn (+10%) was provided, anchored by ~A$0.8bn from acquisitions. Whilst the order book has declined, it continues to give support to the near-term gross margin outlook. Plenty of med-term structural growth initiatives are in play across: consolidation; strategic industry alliances; leading the EV transition; sales channel optimisation; used vehicles; and new markets (offshore). There will be periods of cyclicality experienced through time, however APE is executing on building a sustainably higher earnings base. Add maintained.

1H24 earnings: On trend

Universal Store Holdings
3:27pm
February 22, 2024
UNI’s focus on offering high quality, fashionable apparel in a well presented store environment with high levels of service is paying off. Despite the challenges facing the consumer discretionary market, especially among the younger demographic, the 1H24 performance was highly resilient. Costs were well controlled and margins outperformed expectations, resulting in EBIT coming in 6% above forecast. The core youth consumer appears to be picking up. We have increased our FY24 EBIT estimate by 4% and reiterate our Add rating with an increased target price of $5.65.

Base in place, building future FUM

HMC Capital
3:27pm
February 22, 2024
HMC delivered a strong 1H result driven by growth in the platform (particularly unlisted/private equity funds which have delivered >20% ROE). FY24 pre-tax EPS guidance was provided which includes performance fees and investment gains. The new detail in the result was focussed around future growth areas which was outlined in tandem with a new divisional structure for HMC given the ongoing growth in the platform via the addition of Energy Transition, Capital Solutions and Digital Infrastructure. Areas under development also include global healthcare and private credit. HMC has also attracted high calibre, experienced people to lead. HMC has been a top performer within the sector with the share price +45% over the past year as the strategy continues to bear fruit. We acknowledge the FUM trajectory towards $20bn is becoming clearer with several new initiatives underway and management to execute. However given recent strong performance we move to a Hold rating post result with a revised PT of $7.25 and note there will be a detailed update on new funds with an investor day to be held in 2H24.

Weak headline result, but underlying trends are ok

MA Financial Group
3:27pm
February 22, 2024
MAF’s FY23 NPAT (~A$42m) was -32% on the pcp and ~-12% below consensus (A$47m). Headline result figures disappointed due mainly to higher costs than consensus. Broadly, the build of MA’s underlying business appears to be going ok. However, a difficult cyclical environment and the higher FY23 investment spend repeating in FY24, means upside here is more an FY25 story, in our view. We lower our MAF FY24F/FY25F EPS by -17%/-21% mainly on higher cost assumptions. Our PT is set at A$6.07 (previously A$6.25) on lower earnings estimates offset by a valuation roll-forward. We still see solid medium term value, and maintain our ADD call.

Free cash flow on a super loop and heading higher

Superloop
3:27pm
February 22, 2024
SLC delivered a strong result. EBITDA was a touch below our forecasts (it’s just timing) while FCF was substantially above. FY24 guidance was reiterated. Highlights include: 1) 20% yoy organic revenue growth, 32% including acquisitions; 2) Consumer is flying with record NBN adds continuing to be delivered and consumer revenue lifting 53% yoy and Gross Margin up 75% yoy; 3) SLC reported $1.2m NPATA positive (+114% yoy); and 4) FCF (after finance and rent) jumped an impressive 160% yoy to $9m (88% above our $4.7m forecast). SLC’s fundamentals have improved every reporting period for years now. Unfortunately the share price has not followed the fundamentals higher. In our view this shows a mispricing by the market. We think if equity investors do not properly value the company then it is likely to be in the cross fires as a takeover target. Add and $1.10 target price. Buy SLC before someone else does!

Aerospace & Defence gaining traction

PWR Holdings Limited
3:27pm
February 22, 2024
PWH’s 1H24 result was comfortably above our expectations with growth in Emerging Technologies the key highlight. Divisional revenue growth: Motorsports (ex-Emerging Tech) +5%, Aftermarket +7%, Emerging Technologies +88%, OEM +12%. Key positives: Aerospace & Defence revenue jumped 124% with a stronger pipeline compared to six months ago; EBITDA margin increased 110bp to 28.6% mainly due to an improved sales mix and increased operating efficiency; Balance sheet remains healthy with net cash (ex-leases) of $15.6m. Key negative: ROE fell 100bp to 26.7%. We make minor adjustments to FY24-26 earnings forecasts with EBITDA increasing by between 1-2% and underlying NPAT also rising by 1-2% Our target price increases to $14.25 (from $11.90) reflecting changes to earnings forecasts and a roll-forward of our model to FY25 forecasts. Add rating maintained. While the stock is not cheap (38.4x FY25F PE), we believe PWH is a high-quality business with a strong track record of growth. With a healthy pipeline of opportunities across all key segments (particularly Aerospace & Defence), we expect this growth trend to continue over the long term.

1H24 earnings: Earnings shrunk

The Reject Shop
3:27pm
February 22, 2024
First the good news. TRS outperformed most companies in our coverage universe with +2.3% LFL sales growth in 1H24 (although this was a little less than we had expected). The offering of well-priced every day essentials seems to have resonated with its customers, seeing both transaction and units growth over the period. This has resulted in a shift in sales mix away from general merchandising to the lower margin consumables. Sales momentum continued into the first 7 weeks of 2H24. Then the bad news. There was substantial shrinkage (shoplifting) over the course of the half, impacting EBIT by $4m, which was down 16% yoy. Without this impact, EBIT would have been flat. We maintain our ADD rating on TRS but reduce our target price to $5.40 (was $6.25) due to reduced earnings estimates in the current year.

Delivering on promised returns

Mitchell Services
3:27pm
February 22, 2024
The 1H result was in-line with quarterly reporting, with few surprises. The 2cps interim div reflects a 100% NPAT payout in excess of policy and complimenting accretion from the on-market buyback. The current ex-growth phase looks set to continue, supporting compelling forecast free cash flow yield (22-30%) and dividend yield (9-11%). At only (2.0x FY24F EV/EBITDA MSV still looks disregarded by the market. MSV trades at a sharp discount to direct peers and recent drilling M&A.

Still trying to adjust to the post-COVID world

Healius
3:27pm
February 22, 2024
FY24 underlying profit has been downgraded by double digits, given lower 2H expectations for Pathology volumes and benefits. While 1Q saw high single -digit Pathology volumes and double-digit benefit growth, momentum faded in 2Q, with both metrics tracking in the low single-digit range. It appears soft GP attendances, coupled with labour shortages and inflationary pressures, continue to conspire in holding back volumes. While management is aiming to accelerate Pathology restructuring to better match volumes with costs, activity to date seems to have done little to move the dial, putting greater uncertainty around a solution and complete near-term turnaround. We lower our FY24-26 estimates, with our target price decreasing to A$1.37. Hold.

Less than compelling

Clinuvel Pharmaceuticals
3:27pm
February 22, 2024
CUV’s posted a weaker than expected 1H24 result, with negligible top-line growth combined with a significant increase in the cost base (clinical activity, staff retention incentives and an increase in service roles) to meet future demand. While the top-line growth was disappointing, paired with large cost base increases and Board turnover it failed to inspire much confidence. Investors remain in the dark on US vs EU performance outside of cursory commentary. There was no discussion around capital management plans outside of stockpiling cash, now ~25% of the market cap. We downgrade our target price to A$16 p/s (from A$22 p/s) and recommendation moves to Hold, noting increased risk around board and disclosure. Traders may find an opportunity down here, but equally prepared to wait until a number of investor concerns are addressed.

News & Insights

Investment Watch is a flagship product that brings together our analysts' view of economic and investment strategy themes, sector outlooks and best stock ideas for our clients.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy. This latest publication will cover;

  • Asset Allocation – not the time to play defence
  • Economic Strategy – averting a world recession
  • Equity Strategy – attention turns to August
  • Resources & Energy – domestic gas coming to the boil
  • Banks – befuddling
  • Updated Morgans Best Ideas

Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Download the preview now.

      
View Investment Watch
      

Preview

We think the investment landscape remains favourable. The US economic fundamentals are strong with no significant downside risks to growth in the near-term. European leading indicators suggest a turning point is near and China’s cyclical recovery is still gaining momentum after bottoming earlier in the year.

Meanwhile, the Australian economy continues to defy expectations of a sharper slowdown. In our view, this is not the time to play defence and continue to expect growth assets such as equities and property to do well. This quarter, we look at tactical opportunities in private credit, global equities and across the Australian equity market (resources, agriculture, travel and technology).

Read more
Our best ideas are those that we think offer the highest risk-adjusted returns over a 12-month timeframe supported by a higher-than-average level of confidence. They are our most preferred sector exposures.

As interest rates normalise, earnings quality, market positioning and balance sheet strength will play an important role in distinguishing companies from their peers. We think stocks will continue to diverge in performance at the market and sector level, and investors need to take a more active approach than usual to manage portfolios.

Additions: This month we add Elders.

July best ideas

Elders (ELD)

Small cap | Food/Ag

ELD is one of Australia’s leading agribusinesses. It has an iconic brand, 185 years of history and a national distribution network throughout Australia. With the outlook for FY25 looking more positive and many growth projects in place to drive strong earnings growth over the next few years, ELD is a key pick for us. It is also trading on undemanding multiples and offers an attractive dividend yield.

Technology One (TNE)

Small cap | Technology

TNE is an Enterprise Resource Planning (aka Accounting) company. It’s one of the highest quality companies on the ASX with an impressive ROE, nearly $200m of net cash and a 30-year history of growing its earnings by ~15% and its dividend ~10% per annum. As a result of its impeccable track record TNE trades on high PE. With earnings growth looking likely to accelerate towards 20% pa, we think TNE’s trading multiple is likely to expand from here.

ALS Limited

Small cap | Industrials

ALQ is the dominant global leader in geochemistry testing (>50% market share), which is highly cash generative and has little chance of being competed away. Looking forward, ALQ looks poised to benefit from margin recovery in Life Sciences, as well as a cyclical volume recovery in Commodities (exploration). Timing around the latter is less certain, though our analysis suggests this may not be too far away (3-12 months). All the while, gold and copper prices - the key lead indicators for exploration - are gathering pace.

Clearview Wealth

Small cap | Financial Services

CVW is a challenger brand in the Australian retail life insurance market (market size = ~A$10bn of in-force premiums). CVW sees its key points of differentiation as its: 1) reliable/trusted brand; 2) operational excellence (in product development, underwriting and claims management); and 3) diversified distributing network. CVW's significant multiyear Business Transformation Program has, in our view, shown clear signs of driving improved growth and profitability in recent years. We expect further benefits to flow from this program in the near term, and we see CVW's FY26 key business targets as achievable. With a robust balance sheet, and with our expectations for ~21% EPS CAGR over the next three years, we see CVW's current ~11x FY25F PE multiple as undemanding.

GUD Holdings

Large cap | Consumer Discretionary

GUD is a high-quality business with an entrenched market position in its core operations and deep growth opportunities in new markets. We view GUD’s investment case as compelling, a robust earnings base of predominantly non-discretionary products, structural industry tailwinds supporting organic growth and ongoing accretive M&A optionality. We view the ~12x multiple as undemanding given the resilient earnings and long-duration growth outlook for the business ahead.

Stanmore Resources

Small cap | Metals & Mining

SMR’s assets offer long-life cashflow leverage at solid margins to the resilient outlook for steelmaking coal prices. We’re strong believers that physical coal markets will see future cycles of “super-pricing” well above consensus expectations, supporting further periods of elevated cash flows and shareholder returns. We like SMR’s ability to pay sustainable dividends and its inventory of organic growth options into the medium term, with meaningful synergies, and which look under-recognised by the market. We see SMR as the default ASX-listed producer for pure met coal exposure. We maintain an Add and see compelling value with SMR trading at less than 0.8x P/NPV.


Morgans clients receive full access of the Best Ideas, including our large, mid and small-cap key stock picks.

      
Contact us
      
Read more
There are many reasons to invest in equities. Historically, they have offered higher capital returns than many other asset classes. Furthermore, they provide liquidity and diversification and allow investors to participate in the growth of high performing businesses and sectors.

There are many reasons to invest in equities. Historically, they have offered higher capital returns than many other asset classes. Furthermore, they provide liquidity and diversification and allow investors to participate in the growth of high performing businesses and sectors. Not to be overlooked, however, is their capacity to provide an income stream through regular dividends. In the Month Ahead for July, we highlight a selection of Australian equities that offer superior forecast dividend yields and may be suitable investments for those seeking income.

Happy New Financial Year!

BHP Group (BHP)

BHP Group (ASX: BHP) is the largest diversified mining company in the world. BHP has extensive iron ore, copper, nickel and coal operations, and will soon add potash to its portfolio once its massive Jansen project comes online in late 2026. Besides nickel, which has proven volatile, the rest of BHP’s basket of market exposures share the similar characteristic of typically boasting bumper margins throughout the cycle. Over the last decade BHP has shifted its corporate strategy toward streamlining its business, protecting its balance sheet, slowing its pace of investment and maximising shareholder returns. Despite an impressive shareholder performance over recent years, BHP’s dividend yield has remained above market.

      
BHP coverage report
      

Dalrymple Bay Infrastructure (DBI)

Dalrymple Bay Infrastructure (ASX: DBI). DBI owns a fully contracted coal export terminal in central Qld. It has strong revenue and cost risk mitigants, CPI-linked base revenues boosted by incremental revenues from commissioned sustaining capex projects, very high EBITDA margins, and an investment grade credit profile. Investors comfortable with the coal-related exposure also benefit from the ESG discount imputed into the stock price.

      
DBI coverage report
      

Ventia Services Group (VNT)

Ventia Services Group (ASX: VNT) delivers essential services predominantly to government (c.75% of revenue), with an average contract tenure of c.5-7 years and direct inflation passthrough (95% of revenue) in most contracts. The industry grows at 6-7% pa, with VNT growing 7-10% through industry growth and contract expansion, whilst margins should remain stable. The stock continues to deliver a strong dividend yield, which we expect to continue growing at mid-single digits, whilst trading on an undemanding low double-digit PER.

      
VNT coverage report
      

Eagers Automotive (APE)

Eagers Automotive Limited (ASX: APE) is the leading automotive retail group in Australia and New Zealand, operating for over 100 years and representing a diverse portfolio of OEM (original equipment manufacturer) brands. While current industry dynamics in the auto sector (margin pressure; cost of living impacts) are expected to persist in the near-term, we view the scale operators (such as APE) as best placed to navigate this challenging dynamic. Longer-term, we are positive on APE’s various strategic initiatives and expect it can continue to scale; and sustain a structurally higher return on sales through the cycle.

      
APE research report
      

GQG Partners (GQG)

GQG Partners (ASX: GQG) is global asset management boutique, managing ~US$150bn in funds across four primary equity strategies. We like GQG given its highly effective distribution, scalable strategies, and strong long-term investment performance. We view the earnings tailwind from strong funds under management growth (a combination of investment performance and net fund inflows) will continue and we think GQG will continue to re-rate along with this to a higher earnings multiple in time.

      
GQG research report
      

HomeCo Daily Needs REIT (HDN)

HomeCo Daily Needs REIT (ASX: HDN) has a +$4.5bn real estate portfolio focused on daily needs retail (Large Format Retail; Neighbourhood; and Health Services) across +50 properties with the top five tenants being Woolworths, Coles, JB Hi-Fi, Bunnings and Spotlight. Most of leases are fixed. The portfolio has resilient cashflows, with the majority of tenants being national. Sites are in strategic locations with strong population growth. HDN offers an attractive distribution yield, with a +$600m development pipeline providing further growth.

      
HDN research report
      

IPH Limited (IPH)

IPH Limited (ASX: IPH) is a prominent IP services group with market leading shares in Australia, Singapore and Canada. A defensive business, IPH has strong cash flow generation (with high conversion to EBITDA) and a long-track record of paying dividends to shareholders. We like IPH and consider the return to organic growth (albeit subdued) as a key near-term catalyst for the group. Longer-term, we expect IPH to continue to prosecute its consolidation and network expansion strategy offshore.

      
IPH research report
      

Suncorp (SUN)

Suncorp (ASX: SUN) is well positioned to benefit from continued strong price increases going through the home and motor insurance market in Australia, we expect these price increases to be supportive of SUN’s margins expanding further over the next couple of years. Additionally SUN’s recent divestment of its bank was done at an excellent price and will allow the company to focus completely on its strongest business, general insurance, where it is a market leader.  Finally, post the bank sale, SUN now has >A$4bn of excess capital to return to shareholders, which will occur most likely via the way of a share consolidation and a small special dividend.

      
SUN research report
      

Super Retail Group (SUL)

Super Retail Group (ASX: SUL) is a large discretionary retailer comprising four well-known brands which span several categories, including: Supercheap Auto; rebel Sport; Boating, Camping and Fishing (BCF), and Macpac. We like SUL given its market leading scale (>740 stores), deep data capabilities, strong loyalty base and diversified portfolio of brands. SUL has a very strong net cash balance sheet, and we expect it is positioned for further capital management initiatives in the near-term (i.e. potential special dividends).

      
SUL research report
      

Woodside Energy (WDS)

Woodside Energy (ASX: WDS) is the largest ASX-listed oil and gas producer, and in the top 10 globally. While its share price has come under pressure, Woodside’s fundamentals have benefited from resilient oil/LNG prices, steady group production, progress on delivering its key growth projects, a robust level of profitability, and clear focus on its dividend profile. Woodside’s dividend payout ratio has averaged 80% of earnings for the last +5 years, which is impressive given the last 2 years have been a capex-heavy phase as its progressed construction of the Scarborough, Pluto Train 2, and Sangomar projects. With gearing remaining low and cash flow set to grow post the current investment phase, we see Woodside as likely to remain an attractive yield play.

      
WDS research report
      

Morgans clients receive exclusive insights such as access to the latest stock and sector coverage featured in the Month Ahead. Contact us today to begin your journey with Morgans.

      
Contact Us
      
Read more